Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation

Clinical Nephrology

Volumn 70, Issue 1, 2008, Pages 26-32

  Turk T R ^a   Bandur, S ^b   Nurnberger J ^a   Kribben, A ^a   Mann, K ^a   Philipp, T ^a   Heemann, U ^c   Viklicky, O ^b   Witzke, Oliver ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gliquidone; New onset diabetes mellitus; Renal transplantation; Rosiglitazone

Indexed keywords

ACARBOSE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; GLIQUIDONE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISONE; RAPAMYCIN; REPAGLINIDE; ROSIGLITAZONE; TACROLIMUS;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CAUCASIAN; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GRAFT RECIPIENT; GRAFT REJECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MONOTHERAPY; NEW ONSET DIABETES MELLITUS; POSTOPERATIVE COMPLICATION; PROGNOSIS; RETROSPECTIVE STUDY;

EID: 47549109263     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70026     Document Type: Article

References (24)

1. American Diabetes Association. Standards of Medical Care for Patients with diabetes mellitus. Diabetes Care. 2003; 26: S33-S50.
2. Baldwin D, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation. 2004; 77: 1009-1014.
3. Cosio FG, Kudva Y, Velde M, Larson TS, Textor SC, Griffin MD, Stegall MD. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005; 67: 2415-2421.
4. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Transplantation. 2003; 75 Suppl: 3-24.
5. Fonarow GC. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones. Am Heart J. 2004; 148: 551-558.
6. GlaxoSmithKline. Study no. ZM2005/00181/01: Avandia Cardiovascular Event Modeling Project. (Accessed June 4, 2007, at http://ctr.gsk.co.uk/ Summary/Rosiglitone/III_CVmodeling.pdf).
7. Haering HU, Joost HG, Laube H, Matthaei S, Meissner HP, Panten U, Schernthaner G. Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Evidenz-basierte Diabetes-Leitlinie DDG. Scherbaum WA, Landgraf R (eds). Diabetes und Stoffwechsel. 2003; 12 (Suppl. 2).
8. Hirano Y, Hisatomi A, Ohara K, Noguchi H. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. Transplantation. 1992; 54: 883-887.
9. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) Study: interim findings on cardovascular hospitalizations and deaths. N Engl J Med. 2007; 357: DOI: 10.1056/NEJMoa 073394.
10. International Diabetes Federation. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group. Diab Med. 1999; 16: 716-730.
11. Kerner W, Brueckel J, Boehm BO. Definition, Klassifikation und Diagnostik des Diabetes mellitus. In: Scherbaum WA, Kiess W (eds). Update at http://www.deutsche-diabetes-gesellschaft.de/redaktion/ mitteilungen/leitlinien/EBL_Klassifikation_Update_2004.pdf).
12. Kopitar Z, Koss FW. Pharmacokinetic behaviour of gliquidone (AR-DF 26), a new sulfonyl urea. Summary of the studies so far. Arzneimittelforschung. 1975; 25: 1933-1938.
13. Marceille JR, Goins JA, Soni R, Biery JC, Lee TA. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy. 2004; 24(10): 1317-1322.
14. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002; 25: 583-592.
15. Pietruck F, Kribben A, Ngo Van T, Patschan D, Herget-Rosenthal S, Janssen O, Mann K, Philipp T, Witzke O. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transplant Int. 2005; 18: 483-486.
16. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997; 63: 977-983.
17. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007; 356: 2522-2524.
18. Rote Liste®. Arzneimittelsverzeichnis für Deutschland. Frankfurt/Main, Rote Liste® Service GmbH; 2006.
19. Standl E, Füchtenbusch M. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type 2 diabetes mellitus. Diabetologia. 2003; 46 (Suppl): M30-M36.
20. Sumrani NB, Delaney V, Ding ZK et al. Diabetes mellitus after renal transplantation in the cyclosporine era: an analysis of risk factors. Transplantation. 1991; 51: 343-347.
21. Tamura K, Fujimura T, Tsutsumi T et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding-protein-12 in pancreatic β-cell. Transplantation. 1995; 59: 1606-1613.
22. Türk T, Pietruck F, Dolff S, Kribben A, Janssen OE, Mann K, Philipp T, Heemann U, Witzke O. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant. 2006; 6: 842-846.
23. Vesco L, Busson M, Bedrossian J et al. Diabetes mellitus after renal transplantation. Transplantation. 1996; 61: 1475-1478.
24. Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol. 2005; 16 (Suppl 1): 7-10.